Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Cognitive impairment in multiple sclerosis.
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
RILUTEK®
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Decreased microglial activation in MS patients treated with glatiramer acetate.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

Pages